# Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

> **NCT01444417** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 62 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura
- Thrombocytopenia
- Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
- Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
- Thrombocytopenic Purpura
- Immune Thrombocytopenia

## Interventions

- **DRUG:** Romiplostim
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01444417
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01444417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01444417, "Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01444417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*